Trial Profile
A Double-blinded, Randomized, Controlled, Single Ascending Dose Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2020
Price :
$35
*
At a glance
- Drugs Pudexacianinium (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Astellas Pharma Global Development
- 28 Oct 2020 Results presented in an Astellas Pharma media release.
- 27 Jun 2019 Status changed from recruiting to completed.
- 26 Feb 2019 Planned number of patients changed from 24 to 30.